Almirall to focus on respiratory and skin diseases
Catalan Economy
01 Jan 2010
Pharmaceutical group almirall is to focus its r+d investments on new treatments for respiratory diseases such as asthma and chronic obstructive pulmonary disease (copd) and skin problems, particularly psoriasis and skin cancer.
according to almirall's development director pere berga, the company invested nearly eur 100 million in r&d in 2009. the lab also expects to finalize this year clinical trials for eklira, its new drug for copd. in 2009, almirall posted eur 701 million in revenue, with net profit reaching eur 141 million. the group has a team of 550 researchers at its three centers in sant feliu de llobregat, sant just desvern and sant andreu de la barca (barcelona).
source: expansión 25/01/2010
Related News and Success stories.
-
30 Oct 2024
Catalonia will chair the European Alliance of Semiconductor Regions in 2026
-
29 Oct 2024
Nearly 40 Catalan startups will showcase their technology at three major global industry conferences
-
29 Oct 2024
Catalonia has 340 deep-tech startups, a 6% increase over last year
-
23 Oct 2024
Catalonia is home to 9,602 foreign companies, a record high and a 68% increase over the past decade